Tirzepatide is a weight management research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Tirzepatide is a 39-amino acid synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The molecule is based on a GIP sequence backbone with GLP-1 receptor pharmacophore elements incorporated at key positions, coupled with a C20 fatty diacid chain via a gamma-glutamic acid and mini-PEG linker for albumin binding and extended half-life (~5 days). This dual receptor activation profile distinguishes tirzepatide mechanistically from single-target GLP-1 agonists.
Preclinical and clinical data generated through the SURPASS and SURMOUNT trial programs have established tirzepatide as one of the most studied peptides for metabolic research. In obesity models, tirzepatide produced greater body weight reductions than semaglutide in head-to-head rodent comparisons, attributed in part to GIP receptor-mediated effects on adipose tissue and thermogenesis. Mechanistic research continues to investigate how GIP receptor co-activation modulates the tolerability profile (nausea rates) compared to pure GLP-1 agonism, and how the two receptor pathways interact at hypothalamic, brainstem, and peripheral levels.
PeptidesFromChina.co supplies tirzepatide as a lyophilized powder in sealed vials at ≥98% purity verified by HPLC and mass spectrometry. Certificates of Analysis are available for each batch. All product is intended for laboratory research use only and is not approved for human administration.
| Chemical Class | GIP/GLP-1 Dual Receptor Agonist |
|---|---|
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4813.46 Da |
| Sequence Length | 39 amino acids |
| Half-life (research) | ~120 h (5 days) |
| Receptor Targets | GIPR and GLP-1R |
| Synonyms | LY3298176 |
| Storage | -20°C lyophilized; 4°C reconstituted (up to 28 days) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Tirzepatide | 5 mg | 10 vials | ≥98% | In Stock | $44.00 |
| Tirzepatide | 10 mg | 10 vials | ≥98% | In Stock | $63.00 |
| Tirzepatide | 15 mg | 10 vials | ≥98% | In Stock | $82.00 |
| Tirzepatide | 20 mg | 10 vials | ≥98% | In Stock | $94.00 |
| Tirzepatide | 30 mg | 10 vials | ≥98% | In Stock | $119.00 |
| Tirzepatide | 40 mg | 10 vials | ≥98% | In Stock | $144.00 |
| Tirzepatide | 50 mg | 10 vials | ≥98% | In Stock | $175.00 |
| Tirzepatide | 60 mg | 10 vials | ≥98% | In Stock | $188.00 |
| Tirzepatide | 80 mg | 10 vials | ≥98% | In Stock | $263.00 |
| Tirzepatide | 100 mg | 10 vials | ≥98% | In Stock | $313.00 |
| Tirzepatide | 120 mg | 10 vials | ≥98% | In Stock | $338.00 |
Testing method: HPLC / LC-MS (["HPLC","LC-MS","Endotoxins","Sterility","Water Content","Assay","Visible Particulates","Impurities"]). Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis: Manufacturer COA · Simple COA. Documentation is available for every batch sold.
Tirzepatide has demonstrated particularly pronounced effects on body weight in preclinical and clinical research. In the SURMOUNT-1 trial, weekly subcutaneous administration produced mean body weight reductions of up to 22.5% — exceeding results reported for semaglutide 2.4 mg in the STEP-1 trial under similar conditions. Preclinical rodent models suggest GIP receptor co-activation enhances lipid oxidation in adipocytes and may contribute to preferential fat mass reduction with preservation of lean tissue. These mechanistic questions remain active areas of investigation.
SURPASS clinical trials documented statistically superior HbA1c reductions versus comparator compounds including semaglutide 1 mg, insulin degludec, and basal insulin combinations. Preclinical work in GIP receptor knockout mouse models confirms that the incremental glycaemic benefit of tirzepatide over GLP-1 monotherapy is dependent on intact GIP signalling. Beta-cell preservation and insulinoma cell proliferation assays are used to characterise the cytoprotective component of dual agonism.
The SYNERGY-NASH trial investigated tirzepatide in biopsy-confirmed NASH, reporting histological resolution in a significantly higher proportion of participants versus placebo. Preclinical diet-induced NASH models (CDAA-HFD mice) show reductions in hepatic steatosis, lobular inflammation, and fibrosis staging. The mechanism is thought to involve GLP-1R–mediated hepatic lipid flux reduction and GIP-associated effects on adipose inflammation driving ectopic lipid deposition.
The SURPASS-CVOT (SURPASS-4) trial in subjects with T2D and high cardiovascular risk showed non-inferior and potentially superior trends in MACE versus insulin glargine. Preclinical ApoE⁻/⁻ and LDLr⁻/⁻ atherosclerosis mouse models demonstrate plaque-stabilising effects attributed to anti-inflammatory GLP-1R signalling. Research into tirzepatide's effects on heart failure with preserved ejection fraction (HFpEF) is ongoing in the SUMMIT and SOLSTICE trials.
Semaglutide is a selective GLP-1 receptor agonist with a 31-amino acid backbone. Tirzepatide is 39 amino acids and incorporates both GIP and GLP-1 pharmacophores into a single molecule, enabling simultaneous agonism at two incretin receptors. The dual mechanism produces greater caloric intake suppression and superior weight reduction in head-to-head preclinical and clinical comparisons, and appears to modulate GI tolerability differently from pure GLP-1 agonists.
Tirzepatide lyophilized powder is typically reconstituted in sterile bacteriostatic water (0.9% benzyl alcohol) or PBS, depending on the assay protocol. Allow the diluent to run down the vial wall slowly and swirl gently — do not vortex. Once dissolved, aliquot into single-use volumes and store at 4°C for short-term use (up to 28 days) or re-freeze aliquots at -80°C for longer storage.
Yes. Tirzepatide is used in cell-based receptor activation assays including cAMP accumulation assays in GIP- and GLP-1-receptor expressing HEK293 or CHO cells, and in beta-cell line (MIN6, INS-1) insulin secretion models. Solubility in aqueous buffers is generally sufficient for μM–nM concentration ranges used in standard receptor pharmacology.
Tirzepatide is available through PeptidesFromChina.co on a B2B wholesale basis. Pricing, minimum order quantities, and volume tiers are provided upon request after account verification. Submit an inquiry via the request form or Contact page.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.